ИСТИНА

Разработка новых подходов к иммунотерапии меланомы с использованием персонифицированных противоопухолевых вакцин, направленных на распознавание опухолевых неоантигенов иммунной системой.

Antitumor vaccines that enhance the immune recognition of tumor mutant neoantigens are a promising immunotherapeutic approach to the treatment of malignant neoplasms. The use of high-tech approaches of bioinformatic processing of NGS sequence data based on molecular modeling and trained neural networks will allow selecting from the total mass of SNP mutations those that are expressed tumor-specific immunogenic with a high probability of binding to antigen-presenting complexes. Dendritic cell vaccines loaded with tumor lysate have shown their certain effectiveness, however, loading with a peptide mixture representing simultaneously many specific tumor neoantigens can be highly effective with minimal side effects. Studies of recent decades have shown that most antitumor vaccines themselves are weakly immunogenic and require the use of adjuvants that increase the effectiveness of antigen-specific immune responses, so it is important to search and study the properties of new adjuvants that combine the functions of immune stimulants with the delivery of antigen to immune cells.